Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Contact DCTD
Show menu
Search this site
Last Updated: 09/14/2020

DCTD’s Translational Research Program Announces Fiscal Year 2020 SPORE Grantees

DCTD’s Translational Research Program Announces Fiscal Year 2020 SPORE Grantees

The Translational Research Program (TRP) announced its successfully competed FY2020 Specialized Programs of Research Excellence (SPORE) grantees. The SPORE program uses the P50 and U54 grant funding mechanisms to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites. Including the 2020 grantees, there are now 51 SPOREs located at academic centers in 17 states.

FY 2020 SPORE Grantees

Principal Investigator Institution Cancer Type
** Matthew Ellis Baylor College of Medicine Breast
Simon Powell Memorial Sloan Kettering Cancer Center Breast
Barbara Burtness Yale University Head & Neck
* David McDermott (contact) and
Bill Kaelin
Beth Israel Deaconess Medical Center Kidney
* Roy S. Herbst Yale University Lung
* John Minna (contact), Jack Roth, and John Heymach UT Southwestern Medical Center Lung
Alan D’Andrea (contact),
Ursula Matulonis, and David Spriggs
Dana-Farber Cancer Institute Ovarian

*Grant Renewal    **Grant Renewal/New PI

The goals of the SPORE program include:

  • Translating novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer or at risk for cancer
  • Determining the biological basis for clinical observations
  • Using specimens from clinical studies to determine correlations between biomarkers and outcomes in patients
  • Promoting collaborations between SPOREs, Cancer Centers, other NCI/NIH funded mechanisms and programs, and outside organizations
  • Promoting pilot projects and career enhancement of researchers new to translational research
  • Supporting research in high incidence and rare cancers
  • Encouraging communication with advocates and advocate organizations to obtain advice from the patient perspective

Contact TRP staff for more information on the SPORE program.